(NYSE:WHG),(NYSE:MDST),(NasdaqGM:WEEI), DALLAS, Nov. 04, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group (WHG), a publicly-traded investment management boutique and wealth management firm, today announced monthly income distributions for Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST) and Westwood Salient Enhanced Energy Income ETF (NASDAQ: WEEI) as shown in the table below. This pair of Westwood Exchange- […]

(NASDAQ:RXRX), Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference — Tuesday, November 11, 2025 Jefferies Global Healthcare Conference London — Tuesday, November 18,

(NASDAQ:PTLO), OAK BROOK, Ill., Nov. 04, 2025 (GLOBE NEWSWIRE) — Portillo's Inc. (“Portillo's” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the third quarter ended September 28, 2025. Third Quarter 2025 Performance Highlights (vs. Third Quarter 2024): Total revenue of $181.4 million,

(NasdaqGM:XGN), CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 (Unaudited, in thousands, except ASP data)

(NASDAQ:ERAS), SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investor meetings at

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 in Houston, Texas. https://mma.prnewswire.com/media/2810526/Asahi_Kasei_Corporation_Calliditas_Therapeutics_Logo.jpg The presentations will include new secondary analyses from the Phase 3 NefIgArd study of Nefecon (marketed as TARPEYO® [budesonide] delayed-release

(NYSE MKT:CMT), 2025 Full Year Sales Guidance Down 10% to 12% from Prior Year, and Well-Positioned to Accelerate 2026 New Program Launches COLUMBUS, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in

(NasdaqGM:ENPH), FREMONT, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that its IQ(R) Battery systems are now eligible for San Diego Community Power's (Community Power) Solar Battery Savings program. Community Power is a

(NASDAQ:ARQT), ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics,

(NASDAQ:SABS),(NASDAQ:SABSW), MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases, including its lead program in clinical development for delaying the progression of type 1 diabetes (T1D) in new onset Stage 3 patients, today announced that members of its management team